Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polatuzumab vedotin - Genentech

Next Previous
Drug Profile

Polatuzumab vedotin - Genentech

Alternative Names: ADC DCDS4501A; anti-CD79b-VC-MMAE; Antibody-Drug Conjugate DCDS4501A; DCDS-4501A; FCU-2711; polatuzumab vedotin-piic; polatuzumab vedotin-piiq; Polivy; RG-7596; RO-5541077; RO-5541077-000

Latest Information Update: 25 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Roche; Weill Cornell Medical College
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Phase III Follicular lymphoma
  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Richter's syndrome

Most Recent Events

  • 02 Jul 2025 Québec approves polatuzumab vedotin for public reimbursement for first-line treatment of Diffuse large B cell lymphoma
  • 12 Jun 2025 Updated efficacy and adverse events data from the phase III POLARGO trial in Diffuse large B-cell lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)
  • 08 Dec 2024 Adverse event and efficacy data rom the phase III POLARIX trial in Diffuse large B cell lymphoma released by Genentech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top